Silver Book Fact

Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.

Papaioannaou, Alexandra, Nelson B. Watts, David L. Kendler, Chiu Kin Yuen, Jonathan D. Adachi, and Nicole Ferko. Diagnosis and Management of Vertebral Fractures in Elderly Adults. Am J Med. 2002; 113(3): 220-8. http://www.amjmed.com/article/S0002-9343(02)01190-7/abstract

Reference

Title
Diagnosis and Management of Vertebral Fractures in Elderly Adults
Publication
Am J Med
Publication Date
2002
Authors
Papaioannaou, Alexandra, Nelson B. Watts, David L. Kendler, Chiu Kin Yuen, Jonathan D. Adachi, and Nicole Ferko
Volume & Issue
Volume 113, Issue 3
Pages
220-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.  
  • A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.  
  • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.  
  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.